Have a personal or library account? Click to login
Penicillin allergy management strategies relevant for clinical practice – a narrative review Cover

Penicillin allergy management strategies relevant for clinical practice – a narrative review

Open Access
|Mar 2025

Figures & Tables

Figure 1.

Comparative Overview of the ENDA, Blumenthal, Schrüfer, and PEN-FAST Strategies. Red colour indicates high-risk, yellow represents medium-risk, and green signifies low-risk. The Schrüfer strategy does not specifically define risk classes but recommends delabeling in subjects with affirmative answer to questions 1–3 (graphically associated with green colour) while it recommends avoidance in subjects with affirmative answers to question 5 (graphically associated with red colour). Question 4 appears highligthed in yellow in the original publication. The PEN-FAST scores 4–5 are high-risk (50%), 3 is moderate-risk (20%), 1–2 are low-risk (5%), 0 is very-low-risk of positive penicillin test (<1%). The suggested cutt-of for delabeling is 3. Adapted after Ghiordanescu et al. Comparative Performance of 4 Penicillin-Allergy Prediction Strategies in a Large Cohort. The Journal of Allergy and Clinical Immunology: In Practice. Published online July 2024:S2213219824007438. doi:10.1016/j.jaip.2024.07.012
Comparative Overview of the ENDA, Blumenthal, Schrüfer, and PEN-FAST Strategies. Red colour indicates high-risk, yellow represents medium-risk, and green signifies low-risk. The Schrüfer strategy does not specifically define risk classes but recommends delabeling in subjects with affirmative answer to questions 1–3 (graphically associated with green colour) while it recommends avoidance in subjects with affirmative answers to question 5 (graphically associated with red colour). Question 4 appears highligthed in yellow in the original publication. The PEN-FAST scores 4–5 are high-risk (50%), 3 is moderate-risk (20%), 1–2 are low-risk (5%), 0 is very-low-risk of positive penicillin test (<1%). The suggested cutt-of for delabeling is 3. Adapted after Ghiordanescu et al. Comparative Performance of 4 Penicillin-Allergy Prediction Strategies in a Large Cohort. The Journal of Allergy and Clinical Immunology: In Practice. Published online July 2024:S2213219824007438. doi:10.1016/j.jaip.2024.07.012

Figure 2.

Suggested pathway for the management of patients labeled as allergic to penicillins in non-allergist settings.
Suggested pathway for the management of patients labeled as allergic to penicillins in non-allergist settings.

ENDA, Blumenthal and Schrüfer strategies, classification by risk class and corresponding recommendations

Risk classClinical presentationRecommendations
ENDA
  • Class 1

  • High-risk NIR

SCARs, generalised bullous FDE, severe MPE, linear IgA bullous dermatosis, systemic vasculitides, organ involvement/cytopenia, penicillin-induced autoimmune diseaseavoid using Penicillins/Cephalosporins OR use non-BL antibiotics by microbial coverage OR use, upon graded challenge, Aztreonam, Carbapenems, 3rd/4th/5th generation Cephalosporins
  • Class 2

  • High-risk IR

anaphylaxis, hypotension, laryngeal oedema, bronchospasm, urticaria or angioedema, generalised angioedemaavoid using Penicillins/Cephalosporins OR use non-BL antibiotics by microbial coverage OR use, upon graded challenge, Aztreonam, Carbapenems, 3rd/4th/5th generation Cephalosporins
  • Class 3

  • Low-risk IR, NIR, and unknown reactions

NIR: contact dermatitis, systemic contact dermatitis, local reaction (i.m. administration), exfoliative palmar dermatitis, FDE, delayed urticaria, mild or moderate MPE, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) OR IR: isolated generalised pruritus which did not require treatment, isolated digestive symptoms, localised urticaria OR unknown reactionsavoid using Penicillins/Cephalosporins OR use full-dose Aztreonam, Carbapenems, 3rd/4th/5th generation Cephalosporins OR use non-BL antibiotics by microbial coverage
Blumenthal
  • Class 1

  • High-risk NIR

Stevens-Johnsons syndrome, Toxic Epidermal Necrolysis, Acute interstitial Nephritis, Drug Rash Eosinophilia with Systemic Symptoms (DRESS), haemolytic anaemiaavoid using Penicillins/Cephalosporins, and Carbapenems AND use alternative agents by microbial coverage;
  • Class 2

  • High-risk IR and unknown reactions

anaphylaxis, angioedema, wheezing, laryngeal oedema, hypotension, hives/urticaria OR unknown reactions with no further details available from patient/proxyavoid using the penicillin subclass OR use 3rd/4th/5th generation Cephalosporins by test dose procedure OR use alternative agent by microbial coverage OR use Aztreonam or Carbapenems
  • Class 3

  • Low-risk NIR, EHR and unknown reactions without severity elements

MPE, or minor rash (not hives), EHR mention but patient denies, unknown reaction, but patient denies mucosal involvement, skin desquamation, organ involvement, or need for medical evaluationuse full dose Cephalosporins OR use Penicillin by test dose procedure OR use Carbapenems
Schrüfer
  • Question 5

  • High-risk IR and NIR and reaction during general anaesthesia

chronology of up to 30 minutes from exposure to reaction and a semiology of urticaria or anaphylaxis. signs and symptoms of anaphylaxis occurrence during general anaesthesia mucous membrane erosions/skin bullae hepatic or renal involvement or cytopeniaIf answer is Yes/Uncertain – USE ALTERNATIVE ANTIBIOTIC
  • Question 4

  • MPE

measles-like rash or MPE occurring during or within one week of penicillin exposure?If answer is Yes – USE ALTERNATIVE ANTIBIOTIC (as for high-risk subjects)
  • Question 3

  • Recurrent acute urticaria

acute urticaria with or without angioedema during penicillin exposure which reoccurs for several days after treatment is stopped?If answer is Yes – DELABEL
  • Question 2

  • Skin involvement during childhood/adolescence

skin symptoms such as urticaria and MPE only developed during or immediately after stopping penicillin exposure occurring during childhood or adolescence (less than 16 years)?If answer is Yes – DELABEL
  • Question 1

  • Complaints and timing not compatible with hypersensitivity

symptoms reported are not compatible with a hypersensitivity reaction – gastrointestinal symptoms, cephalea, palpitation? chronology between exposure and symptom onset not suggestive of hypersensitivity – urticaria >2 days after the last dose; MPE >7 days after the last dose?If answer is Yes – DELABEL
DOI: https://doi.org/10.2478/rjim-2024-0035 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Page range: 28 - 38
Submitted on: Nov 29, 2024
|
Published on: Mar 31, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Ileana-Maria Ghiordanescu, Nicolas Molinari, Ana-Maria Forsea, Rik Schrijvers, Cyrille Hoarau, Pascal Demoly, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.